Market Research

Psychedelic Invest is your source for the latest business and investing news about the burgeoning psychedelics industry.

10 Psychedelic Companies Investors Should Have on Their Radar

Nov 9 • 12 min read

Psychedelic drugs are slowly working their way into the mainstream. Major hospitals such as Johns Hopkins are even researching the use of psychedelic drugs like psilocybin and LSD to treat a wide range of mental health conditions. Psychedelics have the potential to treat conditions like depression, anxiety, post-traumatic stress disorder, anorexia, obsessive-compulsive disorder, and addiction. …

What Decriminalization in Oregon and DC Means for Psychedelic Investors

Nov 5 • 3 min read

November 3rd was a historic day for the psychedelic community as three major ballots were passed that will further the adoption of psychedelics. Measure 109 in Oregon: legalizes the use of psilocybin in therapy Measure 110 in Oregon: decriminalizes the possession of psilocybin (and other drugs) Initiative 81 in Washington DC: decriminalizes the possession of…

Mapping Psilocybin Reform: How This Years Election Is Making History [Infographic]

Nov 4 • 1 min read

Psychedelic reform is sweeping the nation. Over the past 18 months five cities and one state have voted to decriminalize psilocybin, and Oregon has gone as far as legalizing psilocybin for therapy. With nearly 100 cities considering decriminalizing psychedelics across the country, this wave shows no signs of slowing down. Below, we cover the timeline…

Oregon Becomes the First State to Legalize Psilocybin for Therapy

Nov 4 • 3 min read

Last night (Nov. 3), voters overwhelmingly called for Oregon to become the first state in the nation to allow the use of psilocybin, the active ingredient in psychedelic mushrooms, in therapy. The vote mandates that the Oregon Health Authority (OHA) will establish a psilocybin-assisted therapy program for adults 21 and older over the next two…

MindMed Raises C$28.75M, Here’s What It’s For…

Nov 3 • 3 min read

On October 30, 2020, Mind Medicine (MMED) closed its previously announced financing, raising C$28.75M (USD $21.74M). The raise was an upsized round from the initial prospectus of C$25,000,500. The company raised the money from institutional investors by issuing 27,381,500 units at a price per unit of $1.05. As we have previously discussed, the unit consisted…

Pages: 1234567891011121314151617181920212223242526272829303132333435363738394041424344454647484950515253